Profile
| Role | Director |
|---|---|
| Notability | 20/100 |
Board memberships
- Turn Therapeutics Inc.
Updated Jul 16, 2026
Gengos Andrew has filed 2 SEC Form 4 filings across 2 companies in the last 90 days.
| Role | Director |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-05 | TERN | Terns Pharmaceuticals, Inc. | D — Derivative transaction | 68.8K | $53.00 | $3.64M |
| 2026-05-05 | TERN | Terns Pharmaceuticals, Inc. | J — Other acquisition / disposition | 40.5K | $53.00 | $2.15M |
| 2026-01-16 | TERN | Terns Pharmaceuticals, Inc. | A — Grant or award | 68.8K | $0.00 | |
| 2025-10-08 | TTRX | Turn Therapeutics Inc. | A — Grant or award | 10.0K | $0.00 |
Gengos Andrew is a corporate insider — currently tracked as Director of Turn Therapeutics Inc. (TTRX). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 2 companies.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Gengos Andrew profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.